Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT04898452
Active, not recruiting Observational

Intravenous Antibiotic Treatment at Home

NCT04898452 · tracked via the Priya Life Science Norway tracker
Phase
Observational
Started
2020-07-02
Last updated
2026-08-24

Condition(s) studied

Infection

Investigational drug(s) / intervention(s)

A new model of interaction across health services with use of welfare technology and telemedicine

A new model of interaction across health services with use of welfare technology and telemedicine: Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.

Study summary

The purpose of the study is to develop and evaluate a new model for across services interaction with the use of welfare technology and telemedicine. The model includes innovative and new routines for the exchange of patient information, quality systems and procedures between the municipality and the hospital. This model will first be tested for use in intravenous antibiotic therapy. The results of the study will be used to further develop the service. In the larger context, it is desirable to provide knowledge that is transferable to other diagnostic groups, treatment methods and geographical areas.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Main or bi-diagnosis during stay: A692 Borreliosis G00 - G009 Central nervous system inflammatory disorders I33 Endocarditis J86 Empyema D46.3 Spondylodiscitis M86 Osteomyelitis T84 Prosthesis / osteosynthesis infections M00.0-M00.9 Pyogen / septic arthritis J40-J47 Chronic diseases of the lower respiratory tract * Competent to give consent * The infection can not be treated with oral antibiotics in monotherapy * Selected IV antibiotics must be suitable for administration via selected pumps * The patient's condition is stable and does not require frequent observation by health care professionals * The patient is motivated and willing to participate in intravenous treatment in home hospitals * Must, after training, demonstrate mastery of practical procedures related to pump handling and any other procedures described in the patient's treatment plan * The home must be suitable for intravenous antibiotic treatment; access to refrigerators, hygienic conditions, social conditions * The patient must have a mobile phone and be able to handle the system for fast and secure communication with the Regional Response Center (RRO) Exclusion criteria: * consent not given

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Helse Møre og Romsdal HF, Kristiansund sjukehus, Medisinsk Avdeling Kristiansund Norway

More Helse Møre og Romsdal HF trials in Norway

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04898452 on ClinicalTrials.gov ↗ ← All trials in Norway